Study tests cost-effective approach utilizing cell-free DNAContinue reading
Category Archives: AZBio News
Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer
Prospective study aimed at analyzing cancer resistance mechanisms using several multiomics technologies with a follow-up period of up to five years.Continue reading
The MedTech Conference 2023: Call for Sessions 2023
Submit session ideas focusing on the latest trends, advancements and critical issues in our field.Continue reading
AZBio Lays Out Goals for It’s Third Decade of Impact
In 2023, AZBio celebrates its first 20 years of impact and targets reaching top-ten status in its 3rd decade.Continue reading
Arizona Governor Katie Hobbs Shares Priorities in 2023 State of the State
The Governor opened her comments with a commitment to focus on creating a better future for every family and communityContinue reading
Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients
MADISON, Wis., December 9, 2022 – Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium® (SABCS®). The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
It’s Time to Apply for Venture Madness 2023
The deadline to apply is Thursday, Jan. 12, 2023 at 3 PM MSTContinue reading
It’s Time to Apply for Start-Up Stadium
Start-up Stadium introduces biotech innovators to investors!
Biotech start-ups: apply to pitch your science at the Start-up Stadium during the BIO International Convention, the largest annual gathering of the biotech community, June 5-8 in Boston.Continue reading
C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform
TUCSON, Ariz., Dec. 20, 2022 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).Continue reading
C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
The iBox Scoring System is available for use in kidney transplant clinical trials as a novel secondary endpoint prognostic for allograft loss.Continue reading